These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

994 related items for PubMed ID: 18639297

  • 1. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z.
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [Abstract] [Full Text] [Related]

  • 2. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z.
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [Abstract] [Full Text] [Related]

  • 3. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [Abstract] [Full Text] [Related]

  • 8. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z.
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [Abstract] [Full Text] [Related]

  • 11. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z, 037 Study Group.
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W.
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.